In one aspect, a method of treating an NK cell to induce a gene edit. The method may include contacting an NK cell with a transfection composition including poly-L-glutamic acid (y- PGA), a single-stranded oligo deoxynucleotide (ssODN) enhancer, or a combination thereof; contacting the NK cell with an editing composition including: a DNA-PK inhibitor, and an HD AC inhibitor; electroporating the NK cell; and contacting the NK cell with a recovery composition including DNase I. In another aspect, a method of preparing an engineered NK cell comprising a fluorescent reporter at an endogenous locus. In another aspect, a method of treating an NK cell to introduce an exogenous nucleic acid.
A surgical kit for providing a cryoprotective composition configured to be applied during cryotreatment of a patient includes: a first container containing a predetermined amount or volume of a biodegradable and/or bioerodible fluid agent; and a second container containing a predetermined amount or volume of a non-toxic cryoprotectant agent. The predetermined amount or volume of the of biodegradable and/or bioerodible fluid agent and the predetermined amount or volume of a non-toxic cryoprotectant agent are configured to be mixed together to form the cryoprotective composition in which a therapeutically effective amount of the cryoprotective composition deposited in a body space of the patient in proximity to the cryotreatment remains within at least a portion of the body space for a duration of the cryotreatment and at least a portion of a body tissue proximate to the body space is viable after the cryotreatment.
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Disclosed herein are compounds of formula
Disclosed herein are compounds of formula
Disclosed herein are compounds of formula
or pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
C07H 19/167 - Purine radicals with ribosyl as the saccharide radical
C07H 19/23 - Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups
5.
HYBRID POLYMERS AND COMPOSITIONS INCLUDING THE SAME
A hybrid polymer may include a hydrophilic block polymerized from a hydrophilic monomer and a hydrophobic block polymerized from at least a quinoline-containing monomer. Polyplex transfection complexes that include a hybrid polymer and an oligonucleotide. Compositions that include a polyplex transfection complex. Methods of using a composition to transfect a cell.
C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Corylus plant named ‘StapN7-6’ that is characterized by its yield of up to nine nuts per cluster (average 4.1/cluster) on terminal stems that are primarily visible outside of the plant's foliage, its relatively medium plant stature and highly suckering and sprawling form, its mid-to late season maturing nut season; maturing in late August to early September in Minnesota, its moderately high nut yields of 294 g of kernel/plant, an average shell-out rate of 34% and an average kernel weight of 0.56 g, its average Modal in-shell nut diameter of 1.6 cm with an average kernel diameter of 1.1 cm, its kernels that are relatively clean of skin and fiber, its in-shell nut sphericity of 91 and a kernel sphericity of 87, and its cold hardiness at least to U.S.D.A. Zone 4b.
Vision-aided inertial navigation techniques are described. In one example, a vision-aided inertial navigation system (VINS) comprises an image source to produce image data at a first set of time instances along a trajectory within a three-dimensional (3D) environment, wherein the image data captures features within the 3D environment at each of the first time instances. An inertial measurement unit (IMU) to produce IMU data for the VINS along the trajectory at a second set of time instances that is misaligned with the first set of time instances, wherein the IMU data indicates a motion of the VINS along the trajectory. A processing unit comprising an estimator that processes the IMU data and the image data to compute state estimates for 3D poses of the IMU at each of the first set of time instances and 3D poses of the image source at each of the second set of time instances along the trajectory. The estimator computes each of the poses for the image source as a linear interpolation from a subset of the poses for the IMU along the trajectory.
G01C 21/16 - NavigationNavigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigatedDead reckoning by integrating acceleration or speed, i.e. inertial navigation
G06T 7/277 - Analysis of motion involving stochastic approaches, e.g. using Kalman filters
This invention relates generally to Bottlebrush polymeric delivery systems. The present polymeric delivery systems may be complexed with biological agents, including nucleic acids, peptides, proteins, or small molecules, for delivery to cells. In particular, the present polymeric delivery systems may be used for delivery of Cas protein in gene editing.
C08F 26/06 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
9.
METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE
Described herein are methods for treating and preventing alloantibody driven chronic graft versus host disease (cGVHD). The methods include administering to an individual in need thereof ibrutinib for treating and preventing alloantibody driven graft versus host disease.
Complexes that include one or more diblock polymers and an oligonucleotide. The diblock polymers can be a cationic polymer, an anionic polymer, or a neutral polymer. The diblock polymer can include a hydrophobic block. Compositions that include a complex. Methods of making the complexes. Methods of using the complexes for transfecting a cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
Disclosed herein are iron complexes and salts thereof comprising a compound of formula (I) as well as materials and devices comprising one or more iron complexes or salts thereof of formula I. Also disclosed herein are methods of using the iron complexes of formula I or salts thereof, such as methods for detecting ions such as phosphate, methods for removing ions such as phosphate from aqueous solutions or mixtures, and methods for treating hyperphosphatemia.
Disclosed herein are iron complexes and salts thereof comprising a compound of formula (I) as well as materials and devices comprising one or more iron complexes or salts thereof of formula I. Also disclosed herein are methods of using the iron complexes of formula I or salts thereof, such as methods for detecting ions such as phosphate, methods for removing ions such as phosphate from aqueous solutions or mixtures, and methods for treating hyperphosphatemia.
A skin-wearable photodetector module includes an array with a plurality of photodetectors and a plurality of optical filters, and each photodetector is configured to receive an optical input from an optical filter having a central wavelength in a wavelength range of about 100 nm to about 1000 nm. Each photodetector includes a substrate with a first major surface having an electrode thereon, and a second major surface overlying an optical filter, an anode within an interior region of the electrode, an active layer including a. ternary mixture of an electron donor, an electron acceptor, and at least one charge carrier trap material, and a cathode that contacts the active layer.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable computer programs for conducting medical and scientific research, clinical research, commercial research and development, assay development, drug discovery, and data analysis, storage, assessment, analytics, assessment, display, and sharing; Downloadable mobile applications for conducting medical and scientific research, clinical research, commercial research and development, assay development, drug discovery, and data analysis, storage, assessment, analytics, assessment, display, and sharing Software as a service (SAAS) services featuring software for conducting medical and scientific research, clinical research, commercial research and development, assay development, drug discovery, and data analysis, storage, assessment, analytics, assessment, display, and sharing
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software in the nature of a mobile application for data collection, data analysis, data display, data distribution, artificial-intelligence powered analysis and content generation, all in the fields of genomics, agronomy, horticulture, agriculture, forestry, agri-food economics and business intelligence, and plant breeding Scientific research; Scientific research consulting; Providing scientific research information; Software as a service (SAAS) services featuring software for data collection, data analysis, data display, data distribution, artificial-intelligence powered analysis and content generation, and for sharing business intelligence all in the fields of genomics, agronomy, horticulture, agriculture, agri-food economics, forestry, and plant breeding; Scientific and technological services, namely, research, analysis, and provision of a searchable database for scientific research in the field of genomics, agronomy, horticulture, agriculture, agri-food economics, forestry, and plant breeding; Providing scientific information in the field of scientific research and scientific data for purposes of genomics, agronomy, horticulture, agriculture, agri-food economics, forestry, and plant breeding
A medical device includes an elongated member configured to be inserted into a vessel of a patient. The elongated member includes a permeable membrane that defines a wall of the elongated member and a flow channel within the wall. The permeable membrane defines nanopores extending from an exterior surface of the permeable membrane to tire flow channel. Idle nanopores are configured to enable diffusion of a pressurized gas from out of the flow channel and. into a fluid within the vessel. The nanopores are configured to form gas nanobubbles at the exterior surface of the permeable membrane as the pressurized gas diffuses out from the flow channel and into the fluid within the vessel.
A triiodothyronine (T3) prodrug, an ionized form thereof, a salt thereof, a hydrate thereof, or any combination thereof. The T3 prodrug includes phosphoric acid ester or an ionized form of a phosphoric acid ester. Pharmaceutical compositions including a T3 prodrug and methods of administering the same. Methods of making a T3 prodrug.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
17.
COMPOSITIONS COMPRISING LIOTHYRONINE AND METHODS OF MAKING THEREOF
Solid pharmaceutical compositions and liquid pharmaceutical compositions that include 3,3',5'-triiodothyronine or a prodrug of 3,3',5'-triiodothyronine, a salt thereof, a hydrate thereof, or any combination thereof. The solid pharmaceutical composition includes an excipient. Methods of making the solid pharmaceutical composition. Methods of administering the solid pharmaceutical compositions and liquid pharmaceutical compositions to a subject.
Provided herein are rapid methods for obtaining an extract of human feces, and methods for using such compositions, including methods for microbiota transplantation therapy, including replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease and/or condition.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Business consulting services for the horticulture industry; Marketing consulting services; Business advice provided to retailers, distributors, farmers, growers, and tree nurseries in the horticulture industry; Business consulting services in the nature of providing business and marketing advice, information, and support to retailers, distributors, farmers, growers, and tree nurseries in the horticulture industry
(2) Horticulture services; Consultancy relating to tree planting; Providing horticultural information in the field of planting, growing, and maintaining trees; Tree renting; Tree nurseries
23.
HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01J 3/40 - Measuring the intensity of spectral lines by determining density of a photograph of the spectrumSpectrography
G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
24.
IRON NITRIDE PERMANENT MAGNET AND TECHNIQUE FOR FORMING IRON NITRIDE PERMANENT MAGNET
A permanent magnet may include a Fe16N2 phase constitution. In some examples, the permanent magnet may be formed by a technique that includes straining an iron wire or sheet comprising at least one iron crystal in a direction substantially parallel to a <001> crystal axis of the iron crystal; nitridizing the iron wire or sheet to form a nitridized iron wire or sheet; annealing the nitridized iron wire or sheet to form a Fe16N2 phase constitution in at least a portion of the nitridized iron wire or sheet; and pressing the nitridized iron wires and sheets to form bulk permanent magnet.
H01F 1/01 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials
B22D 11/06 - Continuous casting of metals, i.e. casting in indefinite lengths into moulds with travelling walls, e.g. with rolls, plates, belts, caterpillars
B32B 15/01 - Layered products essentially comprising metal all layers being exclusively metallic
C21D 1/76 - Adjusting the composition of the atmosphere
H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
A two-phase natural deep eutectic solvent (NADES) generally includes a hydrophilic phase that has at least one hydrophilic component and a hydrophobic phase that has at least one hydrophobic component. In one or more embodiments, the two-phase NADES includes hydrophilic components and hydrophobic components present in a mass ratio of up to 100:1.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Khoruts, Alexander
Bajaj, Jasmohan
Abstract
The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.
A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
27.
PHARMACEUTICAL AGENT CONJUGATES TO MODULATE MACROPHAGE AND INFLAMMATORY FUNCTIONS AND USES THEREOF
The present invention provides a means to target pharmaceutical agents to sites of inflammation within the body using a conjugate that includes the pharmaceutical agent linked by a cleavable linker to a polymer. The conjugate may also include a homing molecule, such as the targeting peptide CRV, linked to the polymer via a second linker. Specifically, the present invention provides the conjugates and methods of using these conjugates to reduce inflammation and treat inflammatory diseases.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
This disclosure describes methods of preparing a decellularized Descemet's membrane and an isolated Descemet's membrane, methods of using an isolated Descemet's membrane, and tissues prepared using an isolated Descemet's membrane. This disclosure further describes a composition that includes an isolated Descemet's membrane. In some embodiments, the tissues and methods described herein may be used to treat a limbal stem cell deficiency or as an ocular surface bandage.
Hermetia illucensHermetia illucens, BSF). In one or more embodiments, the exogenous nucleic acid is integrated into the insect's genome. In one or more embodiments, the transgenic insect exhibits increased production of omega- 3 fatty acids relative to a wild-type insect. In one or more embodiments, the transgenic insect exhibits decreased production of omega-6 fatty acids, omega-9 fatty acids, or both omega-6 fatty acids and omega-9 fatty acids relative to a wild-type insect.
A system for diagnostic screening of a chronic disease includes a test matrix and a user device. The test matrix has a calibration surface including one or more calibration elements and one or more reagents. The user device has image capturing and processing capabilities configured to capture an image and a processor configured to locate, based on the plurality of calibration elements, the test matrix in the image, determine if the test matrix indicates the presence of the chronic disease by comparing a detected contrast of the one or more reagents with the test matrix to an augmented reality trained database, and generate a screening report based on the determination.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Kelly, Rosemary F.
Butterick, Tammy
Shao, Annie
Abstract
The present invention provides extracellular vesicle compositions. Also provided are methods of making an extracellular vesicle loaded scaffold using the extracellular vesicle compositions to increase revascularization. Methods of using the extracellular vesicle compositions and the extracellular vesicle loaded scaffold are provided. The scaffold may increase blood flow and oxygenation of the tissue thereby aiding in treatment of disease and injury.
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (USA)
REGENTS OF THE UNIVERSITY OF MINNESOTA (USA)
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
Inventor
Hamberger, Björn
Reist, Lucas
Buell, Robin
Voytas, Daniel
Deans, Natalie Christine
Cody, Jon
Abstract
Disclosed herein modified tomato plants, plant cells, plant parts, plant seeds, and fruit comprising targeted modifications to endogenous terpene or terpenoid biosynthetic genes resulting in decreased expression of the endogenous terpene or terpenoid biosynthetic gene relative to a reference plant lacking the modification. The decrease of expression in the endogenous terpene or terpenoid biosynthetic gene results in a depletion of carotene in the fruit of the tomato relative to the reference tomato plant lacking the modification. The disclosure further relates to expression of heterologous terpene or terpenoid biosynthetic genes in the modified tomato plants, and related methods and uses.
Certain embodiments of the invention provide a recombinant polypeptide comprising a T5 DNA polymerase amino acid sequence operably linked to a DNA helicase amino acid sequence, as well as methods of using such a recombinant polypeptide for DNA replication and/or mutagenesis. Certain embodiments of the invention provide a targeted artificial DNA replisome complex. Certain embodiments of the invention provide a targeted DNA mutagenesis system.
A method for magnetic resonance image reconstruction with outer volume removal includes accessing timeframes of k-space data acquired using time-interleaved undersampling patterns in k-space. A composite image is generated from the k-space data by combining timeframes of the k-space data. A machine learning model—trained on training data to extract ghosting artifact signal components from a magnetic resonance image—is used to generate a ghosting artifact image by inputting the composite image data to the machine learning model. Outer volume signals are estimated by subtracting the ghosting artifact image from the composite image. Outer volume removed k-space data are generated by removing the outer volume signals from the k-space data. One or more images are reconstructed from the outer volume removed k-space data.
A method includes positioning an ultrasound transducer system to direct focused ultrasound energy into a subject's tissue, configuring the ultrasound transducer system to direct focused ultrasound energy into target nervous system tissue in the subject's tissue configured to cause heating of the target nervous system tissue to reversibly modulate neural activity, and delivering focused ultrasound energy to target nervous system tissue based on the configured ultrasound transducer system. A system includes a dual-mode ultrasound transducer and a controller configured to deliver focused ultrasound energy.
A method for monitoring a magnetic field of a magnetic resonance imaging (MRI) system includes determining a pulse sequence of the MRI system, the pulse sequence having a repetition time (TR) and a readout window repeated for a plurality of repetitions with the TR. A plurality of field measurement segments are also determined, each associated with one of the plurality of repetitions and having a trigger time and a field measurement duration defining a measurement window. The measurement windows collectively span the readout window. The MRI system is used to perform the pulse sequence, measuring MRI data during the readout window while detecting field data using an NMR probe system during the associated field measurement segment. The field data are stitched based on each trigger time of the plurality of field measurement segments, generating a characterization of the magnetic field of the MRI system through the readout window.
G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
G01R 33/58 - Calibration of imaging systems, e.g. using test probes
The invention provides an endovascular device for use in restricting blood flow through the pulmonary artery. The device comprises a smart memory alloy wire frame partially covered with a thermoplastic layer. The device further comprises a screw mechanism coil coupled to the wire frame and/or thermoplastic layer and configured to allow delivery and retrieval of the device.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/00 - Surgical instruments, devices or methods
39.
Vision-Aided Inertial Navigation System for Ground Vehicle Localization
A vision-aided inertial navigation system (VINS) comprises an image source for producing image data along a trajectory. The VINS further comprises an inertial measurement unit (IMU) configured to produce IMU data indicative of motion of the VINS and an odometry unit configured to produce odometry data. The VINS further comprises a processor configured to compute, based on the image data, the IMU data, and the odometry data, state estimates for a position and orientation of the VINS for poses of the VINS along the trajectory. The processor maintains a state vector having states for a position and orientation of the VINS and positions within the environment for observed features for a sliding window of poses. The processor applies a sliding window filter to compute, based on the odometry data, constraints between the poses within the sliding window and compute, based on the constraints, the state estimates.
G01C 21/16 - NavigationNavigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigatedDead reckoning by integrating acceleration or speed, i.e. inertial navigation
G01C 21/28 - NavigationNavigational instruments not provided for in groups specially adapted for navigation in a road network with correlation of data from several navigational instruments
G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
G06T 7/277 - Analysis of motion involving stochastic approaches, e.g. using Kalman filters
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G07C 5/08 - Registering or indicating performance data other than driving, working, idle, or waiting time, with or without registering driving, working, idle, or waiting time
40.
SYSTEMS AND METHODS FOR UNSUPERVISED LEARNING FOR INVERSE PROBLEMS USING COMPRESSIBILITY
In some aspects, the present disclosure provides a computer-implemented method for training a machine learning model to reconstruct an image from subsampled data. The method includes accessing training data, which includes subsampled medical imaging data, with a computer system. The method further includes training a machine learning model on the training data. Training the model includes minimizing a loss function that includes a sparsity term and a consistency term. The sparsity term includes a reweighted norm in a sparsifying transform domain, and the consistency term ensures a non-zero output when the sparsity is minimized. The method further includes storing the machine learning model in the computer system for later use.
Optical systems and methods include and/or implement a light input configured to receive a light from a light source; an optical deflector configured to impart a deflection on the light; an optical redirector configured to relay the deflected light through the optical deflector a predetermined number of times in a loop to create a plurality of virtual deflectors and generate a multiply deflected light; and a light output configured to transmit the multiply deflected light to an external element.
G01S 7/48 - Details of systems according to groups , , of systems according to group
G01S 17/42 - Simultaneous measurement of distance and other coordinates
G02B 17/06 - Catoptric systems, e.g. image erecting and reversing system using mirrors only
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
This invention relates generally to polymeric delivery systems. The present polymeric delivery systems may be complexed with biological agents, including nucleic acids, peptides, proteins, or small molecules, for delivery to cells. In particular, the present polymeric delivery systems may be used in gene editing.
A two-term time lens module, which may be integrated into a microscopy system, receives a first excitation beam and a second excitation beam from a laser source, temporally separates the first excitation beam from the second excitation beam, and provides the temporally separated first and second excitation beams to an imaging device, wherein an amount of temporal separation between the first and second excitation beams imparted by the two-term time lens module is based on at least one of a dispersion property of a material of the sample or a depth of the target location within the sample, such that the excitation beams temporally overlap within a predetermined distance of the depth of the target location and do not temporally overlap at other depths.
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
An intraosseous needle hub includes a hub body and a needle. The hub body has a hollow bore extending along a central axis from a proximal end to a distal end of the hub body. The needle has a hollow bore extending along the central axis and includes a proximal end attached to the hub body, a distal end including a needle tip, a threaded section at the needle tip configured to screw into bone of a patient, and a shoulder portion between the threaded section and the hub body. The shoulder portion is configured to resist movement of the needle through bone of a patient.
The present invention provides compositions of dendritic cells contacted with extracellular vesicles and methods of use thereof. The extracellular vesicles lack or contain a reduce amount of microRNA-424. The dendritic cells may be administered to a subject diagnosed with cancer to treat the cancer or stimulate an anti-tumor response in the subject.
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a CSPG4 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a CSPG4 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A wearable ultrasound transducer device comprises an array of ultrasound transducers (UST array) configured for full-duplex transmit-receive operation. The UST array is supported by a substrate configured for affixation to a body part of a wearer of the device. A controller is operatively coupled to the UST array via a plurality of channel connectors. Each channel connector is coupled to at least one ultrasound transducer of the UST array to define a plurality of channels. A multiplexer is operatively coupled to the channel connectors and the controller. The multiplexer is configured to selectively increase and decrease a number of channels enabled for operation. An input/output (I/O) coupler is operatively coupled to the multiplexer and configured to communicatively couple to, and uncouple from, an imaging console coupler. A portable power source supplies power to the device at least while the I/O coupler is uncoupled from the imaging console coupler.
Provided are compositions for activating NK cells to stimulate an immune response for treating cancer and other disorders. In one embodiment, the invention provides a compound comprising an NK engaging domain that binds to CD16; an NK activating domain operably linked to the NK engaging domain; and a targeting domain that selectively binds to a target cell and is operably linked to the NK activating domain and the NK engaging domain, wherein the targeting domain binds to CLEC12A.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
50.
Multi-Speed Ergonomic Wheelchair And Devices And Methods Therefor
United States Government as Represented by the Department of Veterans Affairs (USA)
Regents of the University of Minnesota (USA)
Inventor
Hansen, Andrew
Voss, Gregory Owen
Nickel, Eric
Goldish, Gary
Looft, John M.
Abstract
A wheelchair having a frame and a drive wheel coupled to the frame. The drive wheel rotates relative to the frame about a first axis of rotation. A first push rim is coupled to the frame. The first push rim rotates relative to the frame about a second axis of rotation that extends substantially parallel to the first axis of rotation. A second push rim is coupled to the frame. The second push rim rotates relative to the frame about a third axis of rotation that extends substantially parallel to the first axis of rotation. A transmission transmits rotation of each of the first and second push rims to the drive wheel. Movement of the first push rim by a first arc length causes the drive wheel to rotate by a first angular displacement, and movement of the second push rim by the first arc length causes the drive wheel to rotate by a second angular displacement that is greater than the first angular displacement.
A61G 5/02 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs propelled by the patient or disabled person
F16H 1/28 - Toothed gearings for conveying rotary motion with gears having orbital motion
F16H 7/02 - Gearings for conveying rotary motion by endless flexible members with beltsGearings for conveying rotary motion by endless flexible members with V-belts
F16H 7/06 - Gearings for conveying rotary motion by endless flexible members with chains
51.
SCALABLE SPINTRONIC DEVICES FORMED ON SILICON WAFERS
Government of the United States of America, as represented by the Secretary of Commerce (USA)
Theiss Research, Inc. (USA)
Inventor
Wang, Jian-Ping
Lyu, Deyuan
Gopman, Daniel B.
Shoup, Jenae E.
Abstract
A device which includes a silicon wafer substrate and a seed layer formed on a surface of the silicon wafer substrate. The device also includes a perpendicular magnetic anisotropy (PMA) layer exhibiting crystalline PMA formed on the seed layer, wherein the PMA structure comprises at least one of iron-palladium (FePd) alloy, iron-platinum alloy (FePt), or iron-platinum-palladium alloy (Fe(PtxPd(1-x)).
A method, and system, for lossless compression of lookup tables, which uses self-similarities, multilevel compression, and higher-bit compression, and in some claims decomposition, to maximize table size savings. The techniques of this disclosure also use addition and arithmetic right shift with several small lookup tables to retrieve original data during the decoding phase. While lookup tables can hold any arbitrary data, most of the claims in this disclosure will focus on applications of lookup tables in function evaluation. Lookup tables may be used either directly for function evaluation or as parts of other table-based methods. In either case, table compression methods can be used to shrink such tables to reduce their implementation hardware costs.
The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and/or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.
A method and a system for thermally or hyperthermally treating an object. A precipitating hydrophobic injectable liquid (PHIL) embolic agent is prepared and enhanced with a magnetic nanoparticle (NP). A delivery device is advanced to a target area and the PHIL−IONP embolic agent is injected directly at the target area. The PHIL and IONPS are observed in-situ using complementary imaging and an impulse is applied to the target area to generate heat sufficient to thermally ablate or induce hyperthymia at the target area. Additional impulses applied to the target areas at later times generate heat sufficient to ablate or induce hyperthymia at the target.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/04 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
In general, disclosed herein are systems and methods of using a monocular camera to determine an estimated time from encounter between an object a region of interest, including receiving an image from a camera, identifying an object from the image, calculating a scaled distance between the object and the region of interest based on the image, calculating a scaled velocity based on the scaled distance, and calculating an estimated time from encounter until the object will encounter the region of interest based on the scaled distance and the scaled velocity.
G06T 7/80 - Analysis of captured images to determine intrinsic or extrinsic camera parameters, i.e. camera calibration
G06V 20/54 - Surveillance or monitoring of activities, e.g. for recognising suspicious objects of traffic, e.g. cars on the road, trains or boats
G06V 20/58 - Recognition of moving objects or obstacles, e.g. vehicles or pedestriansRecognition of traffic objects, e.g. traffic signs, traffic lights or roads
The Connecticut Agricultural Experiment Station (USA)
Inventor
Haynes, Christy L.
Tuga, Beza
Deng, Chaoyi
White, Jason
O'Keefe, Tana
Elmer, Wade
Abstract
A method for improving yield in the genus Glycine wherein the method includes applying mesoporous silica nanoparticles to a seed or plant of a member of the genus Glycine. In particular, the method includes applying chitosan to the mesoporous silica nanoparticles producing chitosan-coated mesoporous silica nanoparticles and applying the chitosan-coated mesoporous silica nanoparticles to the seed or plant.
Provided herein are methods and systems for targeted gene disruption (knock-out, missense mutation) and targeted gene knock-in in mammalian cells using base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Also provided herein are universally acceptable genetically engineered cells comprising targeted disruptions in immunotherapy-related genes and comprising a CAR/TCR for therapeutic applications.
The Trustees of the University of Pennsylvania (USA)
Regents of the University of Minnesota (USA)
Inventor
Riley, James L.
June, Carl H.
Blazar, Bruce R.
Hippen, Keli
Abstract
The present invention provides compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells. Accordingly, the invention provides uses of the expanded nTregs for cellular therapy.
This document describes methods and compositions for producing CD8+ induced Treg (iTreg) cells that include a construct expressing a ligand for use in cell therapy.
Embodiments of the invention provide apparatus, systems, and methods of reducing inflammation. A method of reducing inflammation includes: directing ultrasound at a plurality of blood cells, wherein directing ultrasound at the plurality of blood cells causes a reduction of inflammation associated with the plurality of blood cells. A system configured to reduce inflammation includes: an ultrasound transducer configured to direct ultrasound at a plurality of blood cells to cause a reduction of inflammation due to or associated with the plurality of blood cells.
A flow cytometry system and method including a fluidic transport system with a magnetic separator stage and a detector region with a magnetic detector configured proximate to the detector region of the fluidic transport system; an electronic conditioning system configured to condition an input analog signal from the magnetic detector and output a digital signal; and a computer system with associated software for identifying higher harmonics in the digital signal, and identifying at least one biological molecule according to the identified higher harmonics.
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A device includes a substrate, an electrode, an electrical pad, and a signal line. The signal line is coupled to the substrate and covered by an insulation layer. The signal line is coupled to the electrical pad and the electrode. At least one of the electrode and the signal line includes a diamagnetic material and paramagnetic material, wherein a ratio of the diamagnetic material and the paramagnetic material is selected based on the susceptibility properties of a physiological tissue. The term paramagnetic herein refers to magnetic susceptibility greater than that of the surrounding tissue and diamagnetic refers to magnetic susceptibility lower than that of the tissue.
In a method of identifying a type of AF complexity and/or a treatment of AF based on the type of AF complexity, electrocardiogram (ECG) data associated with a patient is received, the ECG data includes AF signals corresponding to AF episodes. An AF burden (AFB) score is calculated using the ECG data based upon a frequency of the AF episodes or a duration of the AF episodes. An electrical burden (EB) score indicating a variation and distribution of electrical properties of the AF signals is calculated based on EB values of the ECG data in accordance with a plurality of approaches. A complexity AF score is calculated by summing the AFB and the EB scores. A type of AF complexity and/or a treatment is identified based on the complexity AF score. The complexity AF score, the identified type and/or the identified treatment is output on a display device.
The invention is a new and distinct variety of grapevine plant named ‘MN 1325’ that is characterized by its berries that have a crunchy texture, its berries that have a mild labrusca flavor, its berries that have a thick skin, its berries that are suitable for use in baked goods, similar to a blueberry, and its seedless berries (only seed traces).
A digital system that implement functions, including non-linear functions, by breaking the functions into sub-functions such that all the sub-functions have an equal input range. The processing circuitry further uses a number of linear transformations to check if one of the sub-functions can be derived from another sub-function, e.g. to determine self-similarities between the sub-functions. The result is a set of unique, primary sub-functions and a set of secondary sub-functions that may be derived from the primary sub-functions. The processing circuitry of this disclosure is configured to execute instructions that measure pair-wise similarities between sub-functions to find the minimum set of primary sub-functions, from which all the other sub-functions can be derived using a set of bit transformations.
G06F 17/11 - Complex mathematical operations for solving equations
H03K 19/21 - EXCLUSIVE-OR circuits, i.e. giving output if input signal exists at only one inputCOINCIDENCE circuits, i.e. giving output only if all input signals are identical
72.
METHODS AND MATERIALS FOR TREATING PROSTATE CANCER
This document provides methods and materials for treating cancer (e.g., prostate cancer). For example, methods for using one or more agents that can regulate splicing of a nucleic acid (e.g., a precursor-messenger ribonucleic acid (pre-mRNA)) encoding one or more androgen receptor (AR) polypeptides to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer (CRPC)) are provided.
An adenovirus that reduces the extent to which neutralizing antibodies bind to the adenovirus has an AB loop that includes a sufficient portion of the amino acid sequence VTINRSA (amino acids 8-14 of SEQ ID NO:2), TYMLSRN (amino acids 8-14 of SEQ ID NO:3), or STMGTSH motif (amino acids 8-14 of SEQ ID NO:4) to reduce binding of neutralizing anti-adenovirus antibodies compared to an adenovirus having a wild-type AB loop. In some cases, another aspect, the adenovirus has an AB loop that includes a sufficient portion of the amino acid sequence VTINRSA (amino acids 8-14 of SEQ ID NO:2), TYMLSRN (amino acids 8-14 of SEQ ID NO:3), or STMGTSH motif (amino acids 8-14 of SEQ ID NO:4) to reduce hemagglutination compared to an adenovirus having a wild-type AB loop. The adenovirus can be used to deliver therapy to a target cell to which the AB loop binds.
In some aspects, a system for suppressing tinnitus perception of a subject is presented. The system includes an electrical stimulation module including one or more electrical stimulators that are configured to provide electrical stimulation to the subject by producing a series of electrical pulses with a pulse repetition frequency. Each electrical pulse has a pulse duration and current amplitude. The system further includes an acoustic stimulation module that is configured to provide an acoustic stimulation to the subject by producing a soundwave having a frequency range, an acoustic stimulation duration, and frequency-specific amplitudes.
A61F 11/04 - Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense, e.g. through the touch sense
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
The present disclosure relates, in general, to methods for generating engineered antigen-specific T cell receptors, cells and non-human animals comprising such engineered T cell receptors and methods of making engineered T cell receptors. The engineered T cell receptors can be specific for cancer or immunology targets, such as mesothelin, and are useful in developing therapies for cancer, autoimmune diseases, infectious diseases and other conditions or disorders.
The delivery of neurostimulation to a subject using a closed-loop neurostimulation device (e.g., using a brain stimulation device to provide neurostimulation to a subject's brain) is controlled based on a global optimization-based temporal prediction framework. As a result, the brain stimulation device (e.g., a transcranial magnetic stimulation (“TMS”) device) is synchronized with the ongoing neural state (e.g., brain state) in real time. For instance, a brain recording is analyzed to extract the brain process of interest (e.g., frequency of brain oscillations) and used train a prediction algorithm. After that, a stimulation stage is implemented, in which the individual brain state is analyzed in real-time, the occurrence of the biomarkers (e.g., brain oscillation phase) is predicted, and the stimulation is triggered at the expected time.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (USA)
REGENTS OF THE UNIVERSITY OF MINNESOTA (USA)
Inventor
Davila, Marco
Betts, Brian
Abstract
Dual-chimeric antigen receptor (CAR) cell systems are disclosed that can be used with adoptive cell transfer to target and kill cancers expressing tumor antigens (“TA”) that are also expressed on healthy hematopoietic cells. In some embodiments, the dual CAR cell expresses a first CAR polypeptide that contains in an ectodomain a binding agent that can selectively bind CD83 on CD83-expressing cancer cells (“anti-CD83 binding agent”), and a second CAR polypeptide that contains in an ectodomain an antigen-binding agent that can bind a second tumor antigen that is expressed on both the cancer and healthy hematopoietic cells (“anti-TA binding agent”), such as CD33, CLEC12A, CD123, or FLT3.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
78.
SYSTEMS AND METHODS FOR GARMENT FIT GAP MEASUREMENT
A system and method for measuring an air gap between a positive ease garment and an internal structure including a first scanner of a first frequency range; a second scanner of a second frequency range co-located with the first scanner, wherein the second frequency range is different from the first frequency range such that the first scanner and the second scanner differentially reflect off the positive ease garment and the internal structure; and at least one processor in communication with a memory, the memory comprising instructions which, when executed by the processor, cause the processor to perform: receiving a first flight time from the first scanner and a second flight time form the second scanner; determining a difference between the first flight time and the second flight time; estimating, based on the difference between the first flight time and the second flight time, an air gap distance.
The present document relates to an airborne wind-driven energy-converting apparatus, as well as wind-driven energy systems including such an apparatus and methods of producing wind-driven energy.
The invention is a new and distinct variety of grapevine plant named ‘MN 1369’ that is characterized by its seedless berries (small seed traces only), its berries that are medium in size, its berries with a pleasant tropical fruit flavor, its loose berry clusters, its production of berries on secondary buds, and its berries with adherent skin unless overripe.
Some aspects of the present disclosure provide a computer-implemented method for training a nonlinear reconstruction algorithm to reconstruct an image. The method includes accessing magnetic resonance (MR) image data with a computer system. The MR image data include previously reconstructed images that were generating by reconstructing k-space data acquiring with an MRI system. The method further includes using the computer system to train a physics-driven nonlinear reconstruction algorithm having an objective function. The objective function includes a regularization unit and a data consistency unit, which is defined relative to the previously reconstructed images of the MR image data. The method further includes storing the reconstruction algorithm using the computer system.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A biomaterial includes a plurality of thioester functional group linkages and a polymer comprising a plurality of free thiol functional groups. The biomaterial may be configured to undergo shear-thinning when subjected to shear-forces.
A neurostimulation system includes a plurality of stimulation electrodes, a plurality of recording electrodes, a waveform generator in electrical communication with the plurality of stimulation electrodes, and one or more computing devices in electrical communication with the plurality of recording electrodes and the waveform generator. The one or more computing devices cause the waveform generator to electrically excite the plurality of stimulation electrodes of the plurality of stimulation electrodes. After electrically exciting the stimulation electrodes, a neural signal is received from the plurality of recording electrodes. The neural signal is determined to be an electrically evoked compound action potential (“ECAP”) by determining one or more features of the neural signal. One or more stimulation parameters are determined based on one or more characteristics of the ECAP. The waveform generator is then caused to electrically excite the plurality of stimulation electrodes according to the one or more stimulation parameters.
Described here are systems and methods for training a neural network, or other machine learning model, using a cyclic measurement of consistency in a self-supervised learning framework. In general, the disclosed systems and methods implement an uncertainty estimation process that focuses on the data fidelity component of a physics-driven deep learning (PD-DL) model by characterizing the cyclic consistency between different forward models. Subsequently, this uncertainty estimate is used to guide the training of the PD-DL model. It is an advantage of the disclosed systems and methods that this uncertainty-guided PD-DL strategy improves reconstruction quality.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
Engineered cells include modified activity or expression of the protein Noxa from the PMAIP1 gene. In one or more embodiments, the engineered cell is a human cell. In one or more embodiments, the engineered cell includes one or more modifications to the PMAIP1 gene. In another aspect, methods of modulating the activity or expression of the protein Noxa include administering one or more nucleic acids to the cell. In one or more embodiments, the nucleic acids include a gene editing composition.
UNITED STATES GOVERNMENT ADMINSTRATOR OF NASA (USA)
Inventor
Granberry, Rachael
Padula, Ii, Santo
Holschuh, Bradley
Abel, Julianna
Weinberg, Charles
Barry, Justin
Abstract
Yarns incorporating filaments of shape memory materials are described herein that enable the creation of fabrics, garments, and other materials with tunable force absorption or exertion capabilities, as well as creating complex shapes and structures upon actuation. Systems and methods described herein enable selective buckling, recruitment, compression, and other desirable phenomena by actuating fibers in knitted patterns, whether used as isolated filaments or in twisted yarns.
The article includes a porous scaffold structure comprising a plurality of supports. The article further includes a plurality of metallic or non-metallic nanomaterials disposed on at least one of the supports. Each of the plurality of metallic or non-metallic nanomaterials is directly bound to at least one of the supports.
B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
An intranasal composition generally includes hydrocortisone, a hydrocortisone derivative, or a salt thereof. A method of administering an intranasal composition that includes hydrocortisone, a hydrocortisone derivative, or a salt thereof to a subject. A method of treating adrenal insufficiency in a subject, the method includes administering to a subject, a dose of a composition comprising hydrocortisone, a hydrocortisone derivative, or a salt thereof in an amount effective to treat adrenal insufficiency.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
93.
IMPROVED COMPOSITIONS AND METHODS FOR FECAL MICROBIOTA TRANSPLANTATION AND MICROBIOTA TRANSPLANT THERAPIES
The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.
The invention provides a compound of formula (I) or a salt thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and methods of inhibiting an MPC and treating an MPC related disease or condition.
The invention provides a compound of formula (I) or a salt thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and methods of inhibiting an MPC and treating an MPC related disease or condition.
C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
95.
COMPOSITIONS AND METHODS OF TARGETING PYRUVATE KINASE ISOFORM M2 (PKM2)
In certain embodiments, the present invention provides a method of treating a hyperproliferative disorder in a patient in need thereof, comprising administering an agent that induces tetrameric pyruvate kinase isoform M2 (tet-PKM2) to the patient. In certain embodiments, the present invention provides a method of suppressing tumor growth comprising administering an agent that induces tetrameric pyruvate kinase isoform M2 (tet-PKM2) to the patient. In certain embodiments, the present invention provides a method of inducing tetramerization of PKM2 in a cell comprising contacting the cell with TEPP46.
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
96.
POLY-ANTIGEN CYTOKINE-RECEPTOR COMPLEXES (PACCS), COMPOSITIONS, AND METHODS OF USE
A protein complex includes a first protein and a second protein. The first protein includes an IL- 15 domain operably linked to both a first functional domain and a second functional domain. The second protein includes an IL-15Rα domain operably linked to at least one functional domain. In one or more embodiments, at least one of the functional domains is a targeting domain. In one or more embodiments, at least one functional domain includes albumin. In one or more embodiments, the IL15Rα domain is operably linked to two or more functional domains.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Systems and methods for measuring or determining the index of refraction of a material (100) using a clean (low jitter) digital clock signal. An electrical signal, the source clock, is generated and converted to an optical signal. The optical signal is transmitted through the material under test (100) and then detected with an optical sensor (130, 132) that converts the signal back to an electronic signal (the recovered signal). The difference in phase between the source clock and the recovered clock, as generated by a digital dual mixer time difference circuit DDMTD (30), is used to measure the velocity of light in the material under test (100). In some embodiments, the DDMTD (30) incorporates modem RF integrated circuits to achieve a high level of precision, capable of measuring a change in the optical path length of a signal to a precision of 100 femtoseconds, optionally to a precision of 10 femtoseconds.
UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Kumar, Jitendra
Kianian, Shahryar
Alok, Anshu
Steffenson, Brian
Zhang, Feng
Abstract
Wheat Dwarf India Virus (WDIV) nucleic acid constructs and WDIV-associated satellite nucleic acid constructs that can be used for gene editing of both monocotyledonous and dicotyledonous plants are provided herein, as are methods for using the constructs for targeted modification of plant DNA.
The present disclosure relates, in general, to a genetically engineered T cell comprising a modified genome expressing a protein of interest, and use thereof in cell therapy.
A dedicated multiplication circuit includes inputs providing L phases of matrix elements, where each matrix element is a polynomial of x and inputs providing L phases of k vector elements, where each vector element is a polynomial of x. Circuit components perform a multiplication of the matrix and the vector in an NTT domain, wherein the circuit components comprise at most k times (L−1) pointwise polynomial modular multiplication components that receive NTT(xL) as an input.
